Past, Present and Future of Epigenetics in Adrenocortical Carcinoma

Madeleine Ettaieb*, Thomas Kerkhofs, Manon van Engeland, Harm Haak

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

13 Citations (Web of Science)

Abstract

DNA methylation profiling has been suggested a reliable technique to distinguish between benign and malignant adrenocortical tumors, a process which with current diagnostic methods remains challenging and lacks diagnostic accuracy of borderline tumors. Accurate distinction between benign and malignant adrenal tumors is of the essence, since ACC is a rare but aggressive endocrine disease with an annual incidence of about 2.0 cases per million people per year. The estimated five-year overall survival rate for ACC patients is

Original languageEnglish
Article number1218
Number of pages21
JournalCancers
Volume12
Issue number5
DOIs
Publication statusPublished - May 2020

Keywords

  • adrenocortical carcinoma
  • epigenetics
  • DNA methylation
  • ISLAND METHYLATOR PHENOTYPE
  • GROWTH-FACTOR RECEPTOR
  • EUROPEAN NETWORK
  • DNA METHYLATION
  • GENOMIC CHARACTERIZATION
  • PROMOTER METHYLATION
  • PROGNOSTIC ROLE
  • ADRENAL-TUMORS
  • FACTOR-I
  • EXPRESSION

Cite this